BRIEF published on 06/18/2025 at 07:05, 1 year ago PHAXIAM Therapeutics suspends trading of its shares Euronext Paris Innovative Treatments PHAXIAM Suspension Of Quotation Delisting Securities
PRESS RELEASE published on 06/18/2025 at 07:00, 1 year ago Inside Information / Other news releases PHAXIAM Therapeutics suspends trading shares for delisting on Euronext Paris market. No reimbursement to shareholders. Company focuses on innovative phage-based treatments for resistant bacterial infections Trading Delisting Suspension PHAXIAM Therapeutics Phage-based Treatments
BRIEF published on 06/05/2025 at 07:05, 1 year ago PHAXIAM Therapeutics Facing Potential Liquidation Amid Court Hearing Postponement Biopharmaceuticals Judicial Liquidation Court Hearing PHAXIAM Therapeutics Euronext Delisting
PRESS RELEASE published on 06/05/2025 at 07:00, 1 year ago Inside Information / Other news releases PHAXIAM Therapeutics announces new postponement of Offer Review Hearing by Lyon Commercial Court to June 11, 2025. Company to request delisting from Euronext Euronext Delisting Postponement PHAXIAM Therapeutics Lyon Commercial Court
BRIEF published on 03/14/2025 at 17:50, 1 year 3 months ago PHAXIAM Therapeutics seeks buyer in receivership Euronext Paris PHAXIAM Therapeutics Judicial Recovery Looking For A Buyer Extension Of Procedure
PRESS RELEASE published on 03/14/2025 at 17:45, 1 year 3 months ago Inside Information / Other news releases PHAXIAM Therapeutics launches bidding process to find buyers amid receivership, trading of shares to resume on Euronext Paris. Court decides on procedure extension on April 30, 2025 Euronext Paris Receivership PHAXIAM Therapeutics Court Decision Bidding Process
BRIEF published on 03/06/2025 at 18:01, 1 year 3 months ago PHAXIAM Therapeutics Enters Receivership and Delays Financial Results Trading Suspension Financial Results Delay PHAXIAM Receivership Biotech Challenges Court-appointed Administrator
PRESS RELEASE published on 03/06/2025 at 17:56, 1 year 3 months ago Inside Information / Other news releases PHAXIAM Therapeutics announces the opening of a receivership procedure and postponement of its 2024 financial results publication. The company continues operations under observation period Financial Results Biopharmaceutical Company PHAXIAM Therapeutics Receivership Procedure Phage-based Treatments
BRIEF published on 03/06/2025 at 11:45, 1 year 3 months ago Suspension of the Listing of PHAXIAM Therapeutics Euronext Paris Biopharmaceutical PHAXIAM Therapeutics Suspension Of Quotation Resistant Infections
BRIEF published on 12/30/2024 at 17:50, 1 year 5 months ago PHAXIAM Therapeutics: Promising results from the PhagoDAIR pilot study Infection Control PHAXIAM Therapeutics Phase II GLORIA PhagoDAIR Study Anti-S. Aureus Phages
Published on 06/27/2026 at 00:00, 1 hour 4 minutes ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 2 hours 4 minutes ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 2 hours 14 minutes ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 2 hours 49 minutes ago Revive Therapeutics Announces Proposed Private Placement
Published on 06/27/2026 at 00:05, 58 minutes ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 59 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 hour 27 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 hour 27 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 1 hour 36 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
Published on 06/26/2026 at 07:00, 18 hours 4 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 07:30, 1 day 17 hours ago Gimv signs an agreement to acquire Groupe Cap Vert, France’s leading multi-specialist provider of tree and vegetation critical management services, from Ambienta.
